Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 609 in NAFLD
NCT04857606Phase 1Completed
- Sponsor
- Amgen
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing AMG 609 with Placebo (2 arms). Primary endpoints: Subject Incidence of Treatment-emergent Adverse Events, Subject Incidence of Clinically Significant Change from Baseline in Laboratory Analytes and 2 more. Started May 2021; status: completed.
02
Drugs
AMG 609
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04857606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857606.